Probe Drug Cocktail

DRUG3 trials

Sponsors

Eli Lilly and Company, Max Zeller Soehne AG, Michael Hoelscher

Conditions

Drug Interaction StudyHealthyOther Specified Pulmonary TuberculosisPulmonary Tuberculoses

Phase 1

A Study of Multiple Doses of Lasmiditan in Healthy Participants

CompletedNCT03252015

Eli Lilly and CompanyHealthy

Start: 2017-08-15End: 2018-01-02Updated: 2020-01-10

Drug Cocktail Interaction Study of St. John's Wort Dry Extract Ze 117

Max Zeller Soehne AGDrug Interaction Study

Start: 2018-02-05End: 2018-06-23Target: 20Updated: 2018-03-29

BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)

CompletedNCT04044001

Michael HoelscherOther Specified Pulmonary Tuberculosis, Pulmonary Tuberculoses

Start: 2019-11-15End: 2022-05-31Updated: 2022-08-10

Related Papers

Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial.

2025-01-079 citations

Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine

Clinical Pharmacokinetics2021-02-1018 citations